IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free surviva...

✅ 1st Phase III showing MRD (ctDNA)-guided approach in bladder cancer
➡️ Clinical Tip: ctDNA MRD may personalize care & spare low-risk pts from overtreatment.

#BladderCancer #OncoUrology #Immunotherapy #ctDNA #IMvigor011 #Medicalwatch

natera.com/company/news...